Долгая жизнь с муковисцидозом. Коллектив авторов
Чтение книги онлайн.
Читать онлайн книгу Долгая жизнь с муковисцидозом - Коллектив авторов страница 31
![Долгая жизнь с муковисцидозом - Коллектив авторов Долгая жизнь с муковисцидозом - Коллектив авторов](/cover_pre303403.jpg)
264
Høiby N., Ciofu O, Johansen HK, et al. The clinical impact of bacterial bio-films, Int J Oral Sci 2011; 3: 55–65.
265
Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109:317-25.
266
Su S, Hassett DJ. Anaerobic Pseudomonas aeruginosa and other obligated anaerobic bacterial biofilms growing in the thick airway mucus of chronically infected cystic fibrosis patients: an emerging paradigm or "Old Hat"? Expert Opin Ther Targets 2012; 16:859-73.
267
Giliigan PH. Infections in patients with cystic fibrosis: diagnostic microbiology update. Clin Lab Med 2014; 34: 197–217.
268
Zemanick ET, Harris JK, Wagner BD, et al. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoSOne2013;8:e62917
269
Zemanick ET, Harris JK, Wagner BD, et al. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoSOne2013;8:e62917
270
Jones AM. Anaerobic bacteria in cystic fibrosis: pathogens or harmless commensals? Thorax 2011;66:558-9.
271
Zemanick ET, Sagel SD, Harris JK. The airway microbiome in cystic fibrosis and implications for treatment. Curr Opin Pediatr 2011;23:319-24.
272
Smith AL, Fiel SB, Mayer-Hamblett N, et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123: 1495-502.
273
Bryant JM,Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013; 381: 1551-60.
274
Esther CR Jr, Esserman DA, Gilligan R et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-23.
275
Seddon R Fidler K, Raman S, et al. Prevalence of nontuberculous mycobacteria in cystic fibrosis clinics, United Kingdom, 2009. Emerg Infect Dis 2013; 19: 1128-30.
276
Roux A-L, Catherinot E, Ripoll F, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol 2009; 47: 4124-8.
277
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/ IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367–416.
278
Esther CR Jr, Esserman DA, Gilligan R et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-23.
279
Esther CR Jr, Esserman DA, Gilligan R et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-23.
280
Esther CR Jr, Esserman DA, Gilligan R et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-23.
281
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/ IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367–416.
282
Catherinot E, Roux A-L, Vibet M-A, et al. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients. Eur Respir J 2013; 41: 1101-6.
283
Mussaffi H, Rivlin J, Shalit I, et al. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005; 25: 324-8.
284
Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011; 121:3554-63.
285
Catherinot E, Roux A-L, Vibet M-A, et al. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients. Eur Respir J 2013; 41: 1101-6.
286
Binder AM, Adjemian J, Olivier KN, et al. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013; 188: 807-12.
287
Binder AM, Adjemian J, Olivier KN, et al. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013; 188: 807-12.
288
Leung JM, Olivier KN. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin Respir Crit Care Med 2013; 34: 124-34.
289
Leung JM, Olivier KN. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin Respir Crit Care Med 2013; 34: 124-34.
290
Lobo LJ, Chang LC, Esther CR, et al. Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections. Clin Transplant 2013; 27: 523-9.
291
Chotirmall SH, McElvaney NG. Fungi in the cystic fibrosis lung: bystanders or pathogens? Int J Biochem Cell Biol 2014; 52: